{"id":"W4214757615","doi":"10.1093/noajnl/vdac025","title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb Canada","keywords":"Nivolumab; Temozolomide; Medicine; Tolerability; Internal medicine; Oncology; Clinical endpoint; Adverse effect; Radiation therapy; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002447817,0.0003326753,0.001153382,0.0002967665,0.0001457988,0.000008619599,0.0001939695,0.00009523354,0.000233397],"category_scores_gemma":[0.0001965285,0.0002519473,0.00009303103,0.0005680589,0.0002625974,0.0002025769,0.00008081286,0.0003888992,0.000005581959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000509703,"about_ca_system_score_gemma":0.0005492044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002807207,"about_ca_topic_score_gemma":0.002040794,"domain_scores_codex":[0.997382,0.0003528484,0.0006932635,0.0007330544,0.0004212843,0.0004175075],"domain_scores_gemma":[0.9976535,0.001079057,0.0004995598,0.000525268,0.000073367,0.0001692503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2892437,0.01945668,0.3452888,0.0001703108,0.0009433299,0.04989495,0.01260856,0.01025311,0.1741394,0.0000454242,0.00654888,0.09140682],"study_design_scores_gemma":[0.4466616,0.09337346,0.02853223,0.0004419776,0.0008640968,0.001507577,0.009671081,0.00325885,0.154876,0.0001429847,0.259391,0.001279087],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929098,0.003591777,0.00001888981,0.001219633,0.0004267107,0.00129306,0.0002246726,0.00009588603,0.0002195744],"genre_scores_gemma":[0.9947094,0.001441338,0.001536956,0.001092977,0.0001104001,0.0009279767,0.00007437171,0.00006051812,0.00004610051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3167566,"threshold_uncertainty_score":0.9999933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01851337345826857,"score_gpt":0.3102485159173264,"score_spread":0.2917351424590579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}